Del Mar Pharmaceuticals (bc) Ltd.

Phoenix Molecular Designs

Delmar Pharmaceuticals, Inc.

Phoenix Molecular Design

Sandra Dunn

Dennis M Brown

Jeffrey A Bacha

Timothy Scott Daynard

Subhash Annedi

Jaipal Reddy Nagireddy

Aarthi Jayanthan

John H Van Drie

My-my Huynh

Jonathan James Loughrey

Anne Steinø

Elaine McPherson

Richard Winnike

Erik Flahive

Described herein are crystalline forms of (R)-N-(1-(4-aminobenzyl)-1H-pyrazol-4 -yl)-9-methyl-6-oxo-6,7,8,9-tetrahydropyrido [3′,2′: 4,5]-pyrrolo [1,2-a]pyrazine-2-carboxamide hydrochloride and solvates thereof; pharmaceutical compositions and use thereof in treating cancer such as breast cancer, prostate cancer, lung cancer, brain cancer, skin cancer, bone cancer, ovarian cancer, multiple myeloma and leukemia. Compound (I).

Crystalline forms of an RSK inhibitor

The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.

Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multiforme and medulloblastoma

Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem and cancer stem cells including glioblastoma multiforme and medulloblastoma

Described herein are carboxamide derivatives of Formula (II) that are useful as inhibitors of p90 ribosomal S6 kinase (RSK), pharmaceutical compositions comprising the derivatives, and methods of using the derivatives in treating diseases or conditions associated with RSK activity: wherein R, R, R, R, R, and n are defined in the specification.

Substituted tetrahydropyrido[3',2&#x2032;:4,5]pyrrolo[1,2-&#x3b1;]pyrazine-2-carboxamides as RSK inhibitors

Substituted tetrahydropyrido[3',2&#x2032;:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors

The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme. Dianhydrogalactitol acts as an alkylating agent on DNA that creates Nmethylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.

Use of dianhydrogalactitol and analogs and derivatives thereof to treat glioblastoma multiforme

Growing community of inventors

Vancouver, Canada

Sandra Dunn